Publications

Aradi, S, and R Hauser. 2024. “Current Use of Neurotoxins for Alleviating Symptoms of Cervical Dystonia.”. Expert Review of Neurotherapeutics. June 2024 DOI: 10.1080/14737175.2024.2368638.

Hauser, RA, H Barkay, HH Fernandez, J Jimenez-Shahed, SA Factor, N Gross, L Marinelli, et al. 2024. “Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.”. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. Doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21.PMID: 38901008.

Hauser, RA, A Videnovic, P Soares-da-Silva, GS Liang, K Olson, E Jen, JF Rocha, and O Klepitskaya. 2024. “OFF-Times Before, During, and After Nighttime Sleep Periods in Parkinson’s Disease Patients With Motor Fluctuations and the Effects of Opicapone: A Post Hoc Analysis of Diary Data from BIPARK-1 and -2.”. Parkinsonism Relat Disord. 2024 Jun;123:106971. Doi: 10.1016/J.Parkreldis.2024.106971. Epub 2024 Apr 9.PMID: 38631081.

Frank, S, KE Anderson, HH Fernandez, RA Hauser, DO Claassen, D Stamler, SA Factor, et al. 2024. “Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated With Huntington Disease.”. Neurol Ther. 2024 Jun;13(3):655-675. Doi: 10.1007/S40120-024-00600-1. Epub 2024 Apr 1.PMID: 38557959.

Fung, VSC, J Aldred, MP Arroyo, F Bergquist, RA Hauser, M Bouchard, S Bray, et al. 2024. “Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson’s Disease: Considerations for Initiation and Maintenance.”. . Clin Park Relat Disord. 2024 Feb 10;10:100239. Doi: 10.1016/J.prdoa.2024.100239. ECollection 2024. PMID: 38419617.

Comella, CL, J Jankovic, RA Hauser, AT Patel, MD Banach, E Ehler, D Vitarella, RG Rubio, and TM Gross. 2024. “Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.”. Neurology. 2024 Feb 27;102(4):e208091. Doi: 10.1212/WNL.0000000000208091. Epub 2024 Jan 31. PMID: 38295339.

Fernandez, HH, EA Macklin, RA Hauser, KL Chou, YO Cakmak, B Ozsoy, S Fahn, and Parkinson Study Group. 2024. “Intrinsic Auricular Muscle Zone Stimulation for Parkinson Disease: The EARSTIM-PD Phase II Multi-Center Pilot Study Results”. . Parkinsonism Relat Disord. 2024 Apr;121:105959. Doi: 10.1016/J.Parkreldis.2023.105959. Epub 2023 Dec 27. PMID: 38246833.

Trosch, RM, CL Comella, RA Hauser, SN Caroff, WG Ondo, AC Shillington, BJ LaChappelle, CU Correll, and JH Friedman. 2024. “The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.”. J Clin Psychiatry. 2024 Jan 24;85(1):23m14886. Doi: 10.4088/JCP.23m14886. PMID: 38270545.

Hauser, RA, AJ Espay, R Dhall, S Thakkar, L Cloud, L Zietlin, G Banisadr, S Fisher, and H Visser. 2024. “Safety and Efficacy of IPX203 in Parkinson’s Disease: The RISE-PD Open-Label Extension Study.”. Mov Disord. 2024 Feb;39(2):428-432. Doi: 10.1002/Mds.29685. Epub 2023 Dec 18. PMID: 38111267.

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.